SCHEMBL15577495

SCHEMBL15577495

N#Cc1ccc(-c2cnc(O)c(O)c2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 4/20 0.55
FLT1 P17948 1/20 0.55
EGLN3 Q9H6Z9 1/20 0.55
MMP3 P08254 1/20 0.52
MAP4K4 O95819 3/20 0.50
RIPK1 Q13546 1/20 0.50
PARP1 P09874 1/20 0.47
GABRA1 P14867 1/20 0.44
GABRG2 P18507 1/20 0.44
GABRB3 P28472 1/20 0.44
GABRA5 P31644 1/20 0.44
GABRA3 P34903 1/20 0.44
CYP11B2 P19099 1/20 0.43
CA12 O43570 2/20 0.42
CA2 P00918 2/20 0.42
CA9 Q16790 2/20 0.42
CA3 P07451 1/20 0.42
CA6 P23280 1/20 0.42
CA14 Q9ULX7 1/20 0.42
CDK5 Q00535 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15153832 0.83 EGLN1 (0.53) EGLN1FLT1EGLN3MMP3MAP4K4
SCHEMBL14435497 0.83 MMP3 (0.48) EGLN1FLT1EGLN3MMP3MAP4K4
SCHEMBL15577546 0.81 EGLN1 (0.56) EGLN1GABRA1GABRG2GABRB3GABRA5
SCHEMBL15614331 0.76 EGLN1 (0.50) EGLN1MAP4K4CA9CA3CA6
SCHEMBL20646149 0.76 MMP3 (0.57) EGLN1FLT1EGLN3MMP3MAP4K4
SCHEMBL31226302 0.73 MMP3 (0.59) EGLN1FLT1EGLN3MMP3RIPK1
SCHEMBL2141480 0.73 MMP3 (0.59) EGLN1FLT1EGLN3MMP3RIPK1
SCHEMBL28047557 0.71 KIF11 (0.51) EGLN1FLT1EGLN3MMP3MAP4K4
SCHEMBL398888 0.71 NPC1 (0.54) EGLN1FLT1EGLN3MMP3MAP4K4
SCHEMBL9024270 0.71 CYP11B2 (0.50) EGLN1FLT1EGLN3MMP3MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9932323-B2 Therapeutic hydroxypyridinones, hydroxypyrimidinones and hydroxypyridazinones RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2018-04-03 US disclosed
US-20170204083-A1 THERAPEUTIC HYDROXYPYRIDINONES, HYDROXYPYRIMIDINONES AND HYDROXYPYRIDAZINONES RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2017-07-20 US disclosed
US-9573938-B2 Therapeutic hydroxypyridinones, hydroxypyrimidinones and hydroxypyridazinones RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2017-02-21 US disclosed
US-20150232454-A1 THERAPEUTIC HYDROXYPYRIDINONES, HYDROXYPYRIMIDINONES AND HYDROXYPYRIDAZINONES RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2015-08-20 US disclosed
WO-2014043252-A2 THERAPEUTIC HYDROXYPYRIDINONES, HYDROXYPYRIMIDINONES AND HYDROXYPYRIDAZINONES RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2014-03-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170204083-A1 THERAPEUTIC HYDROXYPYRIDINONES, HYDROXYPYRIMIDINONES AND HYDROXYPYRIDAZINONES XDH, DPYD, P4HA1 EGLN1 56/4885FLT1 1059/4885EGLN3 23/4885
US-20150232454-A1 THERAPEUTIC HYDROXYPYRIDINONES, HYDROXYPYRIMIDINONES AND HYDROXYPYRIDAZINONES XDH, DPYD, DHX15 EGLN1 59/4885FLT1 1038/4885EGLN3 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.